NCHR agrees with AHRQ draft review designed to enhance care for women with postpartum hypertensive disorders of pregnancy. We are encouraged by the focus on the important issue of maternal mortality and look forward to seeing a meaningful response by policymakers.
Read More »Author: Caroline Bradford
NCHR Comments on USPSTF Draft Recommendation Statement Regarding Screening for Hypertensive Disorders of Pregnancy
March 6, 2023: We strongly support the US Preventive Services Task Force draft recommendations that all asymptomatic pregnant women be screened for high blood pressure throughout pregnancy. We appreciate the agency considering how screening will help prevent medical problems for mothers and babies that could be caused by hypertensive disorders of pregnancy.
Read More »Meeting of Patient, Consumer, and Public Health Coalition with Commissioner Califf and Key FDA Officials
March 1, 2023: As a leader of the Patient, Consumer, and Public Health Coalition, the National Center for Health Research scheduled a meeting at the FDA with Commissioner Califf and other key FDA officials to discuss accelerated approval, lab developed diagnostic tests, and improvements to FDA Advisory Committees.
Read More »The Obesity Revolution
STAT, March 5, 2023: Novo Nordisk makes a popular weight loss drug and they want doctors to prescribe it. They have paid for materials to teach medical students that weight loss drugs are effective, and we tell STAT that med students are a captive audience and shouldn’t be taught by a company that sells the drugs that they are learning about. That doesn’t just push the envelope, it shreds it.
Read More »FDA could widen path for OTC birth control, statins
Roll Call, March 2, 2023: Roll Call explains that FDA proposes broadening access to some common medications that currently require a doctor’s prescription. FDA suggests replacing prescriptions with a short quiz for over-the-counter access. We ask if patients will be careful enough to safely use these products.
Read More »